Browse ALDH3B2

Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Lipid droplet
Domain PF00171 Aldehyde dehydrogenase family
Function

Oxidizes medium and long chain aldehydes into non-toxic fatty acids.

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006067 ethanol metabolic process
GO:0006068 ethanol catabolic process
GO:0006643 membrane lipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0030148 sphingolipid biosynthetic process
GO:0034308 primary alcohol metabolic process
GO:0034310 primary alcohol catabolic process
GO:0044282 small molecule catabolic process
GO:0046164 alcohol catabolic process
GO:0046467 membrane lipid biosynthetic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901616 organic hydroxy compound catabolic process
Molecular Function GO:0004028 3-chloroallyl aldehyde dehydrogenase activity
GO:0004029 aldehyde dehydrogenase (NAD) activity
GO:0004030 aldehyde dehydrogenase [NAD(P)+] activity
GO:0016620 oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor
GO:0016903 oxidoreductase activity, acting on the aldehyde or oxo group of donors
Cellular Component GO:0005811 lipid particle
> KEGG and Reactome Pathway
 
KEGG hsa00010 Glycolysis / Gluconeogenesis
hsa00340 Histidine metabolism
hsa00350 Tyrosine metabolism
hsa00360 Phenylalanine metabolism
hsa00410 beta-Alanine metabolism
hsa00980 Metabolism of xenobiotics by cytochrome P450
hsa00982 Drug metabolism - cytochrome P450
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1660661: Sphingolipid de novo biosynthesis
R-HSA-428157: Sphingolipid metabolism
Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ALDH3B2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ALDH3B2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ALDH3B2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.5560.0389
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.6090.22
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.5320.142
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5210.554
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.060.97
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2550.514
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2290.821
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.880.544
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.4280.348
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.050.904
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.050.937
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3510.2
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ALDH3B2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ALDH3B2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ALDH3B2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ALDH3B2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ALDH3B2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ALDH3B2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ALDH3B2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolALDH3B2
Namealdehyde dehydrogenase 3 family, member B2
Aliases aldehyde dehydrogenase 8; acetaldehyde dehydrogenase 8; ALDH8; Aldehyde dehydrogenase family 3 member B2
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ALDH3B2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ALDH3B2.
ID Name Drug Type Targets #Targets
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144
DB09116Calcium carbimideSmall MoleculeALDH3B21